Results 21 to 30 of about 2,141 (187)

Successful treatment of SAPHO syndrome with oral abrocitinib: a case report

Journal of Dermatological Treatment
Aim SAPHO (synovitis, acne, pustulosis, hyperostosis and osteitis) syndrome is a rare autoimmune disorder characterized by typical cutaneous lesions (palmoplantar pustulosis and eruptive acne) and osteoarticular symptoms (aseptic osteomyelitis and joint ...
Zhipeng Lin
exaly   +3 more sources

Effectiveness of Abrocitinib in Cyclosporine-Resistant Atopic Dermatitis: A Real-world Experience from the Indian Subcontinent [PDF]

Indian Journal of Dermatology
Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by pruritus and eczematous lesions. Abrocitinib, a selective Janus kinase 1 (JAK1) inhibitor, has recently been approved in India for moderate-to-severe AD in adults.
Abhishek De, Disha Chakraborty, S. K. Shahriar Ahmed, Smriti Gupta, Sandipan Dhar, Manas Chatterjee   +5 more
doaj   +2 more sources

Long-Term Effectiveness and Safety of Abrocitinib in Patients with Atopic Dermatitis: A Real-World, Retrospective Study [PDF]

Dermatology and Therapy
Introduction Abrocitinib constitutes one of the most effective therapeutic agents for the treatment of atopic dermatitis (AD). However, real-world data validating its effectiveness outside randomized controlled trials remain limited and are primarily ...
Aikaterini Tsiogka, Ioannis-Alexios Koumprentziotis, Ileana Afroditi Kleidona, Aristeidis Vaiopoulos, Michail Bakakis, Eleni Hatzidimitriou, Mariana Vasilopoulou, Theodora Douvali, Alexander Stratigos, Stamatios Gregoriou   +9 more
doaj   +2 more sources

Tailoring Abrocitinib Treatment for Moderate-to-Severe Atopic Dermatitis to Patient Disease Course: A Narrative Review [PDF]

Dermatology and Therapy
Atopic dermatitis (AD) is a chronic inflammatory skin condition characterized by intense itching, redness, and eczema. It significantly impacts the quality of life of affected individuals, often requiring long-term management strategies.
Jonathan I. Silverberg, Eric Simpson, Melinda Gooderham, Stephan Weidinger, Melissa Watkins, Justine Alderfer   +5 more
doaj   +2 more sources

Comparative Analysis of the Efficacy of Abrocitinib and Dupilumab in the Treatment of Atopic Dermatitis [PDF]

Clinical, Cosmetic and Investigational Dermatology
Dan Song, Wei-Ping Gong, Gui-Lin Xiao Department of Dermatology, Zhoushan Hospital, Zhoushan City, Zhejiang Province, 316000, People’s Republic of ChinaCorrespondence: Dan Song, Department of Dermatology, Zhoushan Hospital, No.
Song D, Gong WP, Xiao GL
doaj   +1 more source

Abrocitinib alleviates the symptoms of Netherton syndrome and is well tolerated

Journal of Dermatological Treatment
Purpose To investigate the potential genetic basis of Netherton syndrome (NS) through first- and second-generation DNA sequencing techniques. Additionally, we evaluated the therapeutic efficacy of Abrocitinib in NS patients.Materials and methods We ...
Jun-Ting Tang, Yu-Liang Qin, Wei-Jia Zhao, Ying Tu, Dong-Jie Sun   +4 more
exaly   +3 more sources

Abrocitinib Treatment in Diffuse Alopecia Areata: A Case Report and a Literature Review. [PDF]

Clin Case Rep
ABSTRACT Alopecia areata is an autoimmune disease with diverse clinical manifestations. This case report describes a patient with diffuse alopecia areata who responded well to oral abrocitinib, resulting in complete hair regrowth. The patient achieved complete recovery without any observed adverse effects.
Zhang X, Zhong J, Wu L, Yang P, Zhao X, Luo Y, Qiu Y.   +6 more
europepmc   +2 more sources

Case report: Exploration of abrocitinib in the treatment of refractory chronic spontaneous urticaria: a case series

Frontiers in Immunology
In clinical practice, some cases of chronic spontaneous urticaria (CSU) remain difficult to treat, with up to 40% of patients showing no response to even high (4-fold) daily doses of antihistamines.
Na Du, Dan Wang, Jingyi Yang, Yiwen Zhang, Xinyan Lyu, Wei Min, Sicheng Zhao   +6 more
exaly   +3 more sources

Abrocitinib may improve itch and quality of life in patients with itch‐dominant atopic dermatitis

Skin Health and Disease
Background Patients with atopic dermatitis (AD) exhibit heterogeneous clinical phenotypes, reflecting different combinations of itch and lesional severity.
Jonathan I. Silverberg, Jacob P. Thyssen, Irina Lazariciu, Daniela E. Myers, Erman Güler, Raj Chovatiya   +5 more
doaj   +2 more sources

Effect of abrocitinib on skin biomarkers in patients with moderate-to-severe atopic dermatitis [PDF]

, 2023
Background: This is the first report on the effects of abrocitinib, a Janus kinase 1–selective inhibitor, on the expression of skin biomarkers in patients with moderate-to-severe atopic dermatitis (AD).
EYERICH, K., CHEN, A., WEIDINGER, S., DA ROSA, J.C., ESTRADA, Y.D., PAGE, K.M., GÜLER, E., FACHERIS, P., DEL DUCA, E., SENESCHAL, Julien, BOSE, S.N., ARMSTRONG, A.W., GOMEZ-ARIAS, P.J., XU, D., CHAN, G., BISSONNETTE, R., TATULYCH, S., GUTTMAN-YASSKY, E., KERKMANN, U.   +18 more
core   +3 more sources